Patients with chronic kidney disease (CKD) have markedly higher rates of severe vitamin D deficiency and reduced ability to convert 25-(OH)vitamin D into the active form, 1,25-dihydroxyvitamin D [1] . In the setting of CKD, secondary hyperparathyroidism develops as a consequence of reduced renal production of active vitamin D and phosphate retention resulting in hypocalcaemia and hyperphosphataemia. This is a process that is dangerously linked with metabolic bone disease, arterial calcifications and cardiovascular mortality [2] . Therefore, the conventional rationale for vitamin D treatment in CKD is to slow the progression of secondary hyperparathyroidism.
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In addition to the classical pathway for activation of 25-(OH)vitamin D to 1,25-(OH) 2 vitamin D, a peripheral autocrine pathway exists and results in calcitriol synthesis in a variety of peripheral extra-renal tissues [3] . By binding with its intracellular vitamin D receptor (VDR) in these tissues, calcitriol can regulate cellular proliferation and differentiation, inflammation, the immune system and the endocrine system, including insulin resistance, lipid metabolism and renin-angiotensin system (RAS) [4] . Interestingly, active vitamin D analogues have shown demonstrably favourable effects on proteinuria, likely through interference with RAS [5, 6] . The discovery of this non-classical pathway has brought new significance to the importance of addressing nutritional vitamin D deficiency [7] .
Vitamin D deficiency has been associated with all-cause and cardiovascular mortality in patients with CKD, whereas therapies with vitamin D and analogues have been associated with reduced mortality, recently also in meta-analysis of observational studies (Table 1) . However, evidence from randomized controlled trials (RCTs) supporting a survival benefit from active and/or pre-active vitamin D administration in CKD patients is still lacking. Moreover, it is not even known whether different types of active vitamin D, selective or non-selective VDR activators, or precursors have a diversified effect on mortality in the CKD population.
In the present issue of the Clinical Kidney Journal, Mann et al. [8] present a meta-analysis of RCTs to investigate the effect of oral vitamin D therapy versus placebo on mortality and cardiovascular outcomes among adults with CKD, whereas vitamin D supplementation was not found to exert any significant effect on these hard outcomes. Analysis of pooled data displayed a substantial overlap in confidence intervals and homogeneity between study results. Stratification of trials by CKD stage, weekly vitamin D dose, proportion of diabetic subjects and vitamin D compound displayed similar results. In detail, 13 trials that, overall, enrolled 1469 patients with CKD stage 1-5D were selected for analysis and none of them had mortality as a primary outcome. These studies were mainly designed to test biochemical or bone histological end points and consequently had a rather short follow-up. On the whole 41 all-cause deaths (2.8%) were recorded during a follow-up ranging from 3 to 104 weeks (mean 41 weeks). Of note, about two-thirds of the patients (n = 1087) had been followed for <1 year (mean 21, range 3-48 weeks), registering 17 all-cause deaths (41%), 8 cardiovascular deaths (62%) and 18 cardiovascular events (86%). Only two trials (total patient number = 233) had a follow-up time up to 2 years, but they registered only 11 deaths of which, 5 had a cardiovascular cause. Taken together, these observations could indicate that the duration of follow-up may have been insufficient to capture possible differences in mortality, as correctly stated from the authors in the limitation section and as well as suggested by the relatively low number of events displayed.
Moreover, not negligible differences are also present in patient populations (End Stage Renal Disease in 5 of 13 trials) and in interventions, above all considering the heterogeneity in administered vitamin D compounds and dosages.
In conclusion, it is not the time to say that interventions based on vitamin D may reduce mortality in patients with CKD, but the opposite cannot be said yet beyond all Editorial Comment reasonable doubt. In fact, given the paucity of good quality data, the reliability of the pooled results is still uncertain. 
